Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

Regeneron Pharmaceuticals had previously agreed to acquire the company for $256 million. TTAM’s higher bid and added consumer protections ultimately led the board’s special committee to select it as ...

Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...

A nonprofit led by the co-founder and former CEO of 23andMe outbid competitors for nearly all of the company’s assets.

Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.

DNA firm 23andMe fined £2.31m by UK regulator for a 2023 data breach that exposed sensitive health and family information. Sale to TTAM Research to include stricter privacy commitments.

Beleaguered genetic testing company 23andMe announced Friday that it has reached an agreement to sell itself to TTAM Research ...

Anne Wojcicki's nonprofit will acquire substantially all of 23andMe's assets for $305 million, the company announced Friday.

In a recent investigation we took a hard look at the cybersecurity practices of major direct-to-consumer DNA testing ...

Anne Wojcicki's nonprofit is set to purchase all significant assets of the bankrupt genetic testing company, 23andMe, for ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

The DNA data of more than 15 million customers of DNA testing firm 23andMe is set to be returned to the control of 23andMe co ...